Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas
/PRNewswire/ -- Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its...